Close on the heels of the Intellectual Property Appellate Board halting Novartis' Glivec patent application...on account of its high prices, the Delhi High Court has dealt a body blow to German drug maker Bayer's ambitions to monopolise the Indian market with its kidney cancer drug Nexavar...There is every possibility that multinational companies will not hurry into launching new products in India and blame it on an ambiguous patenting system...The better and more reasonable option could be to introduce products in India at an Indian pricing. That way, the vast population here can afford drugs and multinational companies can make volume-based profits rather than value-based profits. [also refers to Cipla]